Stockreport

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Zealand Pharma A/S - American Depositary Shares  (ZEAL) 
Last zealand pharma a/s - american depositary shares earnings: 11/15 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: zealandpharma.com
PDF The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetesThe Phase 2 trial for BI 456906 is expecte [Read more]